3174
CSOP China Healthcare Disruption ETF
NAV as of
4 Week: 2.40 - 2.58
52 Week: 2.39 - 3.92
Latest Closing Price
2.47
Premium / Discount
0.94
Expense Ratio
0.99%
Investment Objective
The investment objective of the Sub-Fund is to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Index, namely, Solactive China Healthcare Disruption Index (the “Index”). There is no assurance that the Sub-Fund will achieve its investment objective.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -28.93 | 1.97 | -14.70 |
| 1 Day | 2.58 | 0.00 | 0.00 |
| 1 Week | -1.52 | 5.01 | -0.30 |
| 1 Month | 1.99 | 8.63 | 0.23 |
| 3 Months | -5.81 | 16.01 | -0.36 |
| 6 Months | -22.21 | 21.15 | -1.05 |
| 1 Year | -6.09 | 37.04 | -0.16 |
| 2 Years | -62.15 | 59.33 | -1.05 |
| 3 Years | 0.00 | 0.00 | 0.00 |
| 5 Years | 0.00 | 0.00 | 0.00 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | -27.3472 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 88.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| N.A | ||
Portfolio Data
Total Number of Holdings: 36
Number of Bond Holdings: 0
Number of Equity Holdings: 35
Total Market Value: 25,950,391
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | WuXi Biologics (Cayman) Inc | 8.4342 | 51,318 | 0 | 2,188,713 |
| 2 | Wuxi AppTec Co Ltd | 8.3164 | 25,271 | 0 | 2,158,143 |
| 3 | JD Health International Inc | 7.1847 | 44,765 | 0 | 1,864,462 |
| 4 | Shanghai Fosun Pharmaceutical (Group) Co Ltd Class | 6.0361 | 85,689 | 0 | 1,566,395 |
| 5 | CSPC Pharmaceutical Group Ltd | 5.6488 | 253,613 | 0 | 1,465,883 |
| 6 | Alibaba Health Information Technology Ltd | 5.2318 | 289,484 | 0 | 1,357,680 |
| 7 | Hansoh Pharmaceutical Group Co Ltd | 4.8344 | 126,085 | 0 | 1,254,546 |
| 8 | Innovent Biologics Inc | 4.7234 | 32,730 | 0 | 1,225,738 |
| 9 | Sino Biopharmaceutical Ltd | 4.5563 | 402,167 | 0 | 1,182,371 |
| 10 | Genscript Biotech Corp Class H | 3.4619 | 45,511 | 0 | 898,387 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 16.75 |
| Large | 59.25 |
| Medium | 20.23 |
| Small | 3.46 |
| Micro | 0.00 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
19.5964
Price/Book*
2.1342
Price/Sales*
2.4859
Price/Cash Flow*
16.2141
Dividend Yield*
1.3347
Growth Measures
Long-Term Earnings
13.1686
Historical Earnings
2.9160
Sales Growth
14.5289
Cash-Flow Growth
4.5301
Book-Value Growth
10.7072
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
